3DS’ Genomic Imaging for Precision Medicine

As CEO of 3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) since last September, Jason Flowerday is putting the diagnostic company on people’s radar. Unlike most diagnostic companies, 3DS’ proprietary imaging software, known as TeloView, goes beyond identifying whether a patient suffers from a specific condition. By analyzing a patient’s chromosomal arrangement, or signature, TeloView can help doctors tailor personalized treatment and manage each individual patient. With two decades of executive life sciences management and start-up experience, including successive roles at Bayer and J&J, Mr. Flowerday’s mission at 3DS is to transform a highly promising platform technology into a commercial reality with U.S. partners, focusing on those tests that can deliver early value and broaden the company’s development program. In this interview with BioTuesdays, Mr. Flowerday discusses recent advances in 3DS’ lead diagnostic programs and their application to drug development.

Let’s begin with a brief history of 3DS.

The company was co-founded in 2014 by Dr. Sabine Mai, our principal inventor. She began her research over 20 years ago and discovered that the 3-dimensional arrangements of telomeres, which are located at the tips of each chromosome, represent a new class of biomarkers. Her research explored 13 different cancers and Alzheimer’s disease and concluded that by analyzing telomeres and their organization, we have the potential to determine how a disease will progress and if a patient will respond to specific treatment. This information enables clinicians to measure the appropriateness and effectiveness of different treatment options for each individual patient.

Can you give us a description of your technology?

Using fluorescent markers and high-resolution microscopes, the location of each telomere within the cell nucleus can be visualized and digitally analyzed. And using 3DS’ TeloView software platform, the 3-dimensional organization of telomeres within a given cell becomes highly predictive of the disease status of a particular patient. So what all this means is that we have the ability to identify the structural organization of a patient’s chromosomes, which is a measure of genomic instability. And by mapping telomere signatures and measuring the level of genomic instability, we can potentially predict the aggressiveness of a disease and drug responsiveness. The technology is well developed and supported by 22 clinical studies on over 2,000 patients in 13 different cancers and Alzheimer’s disease.

What’s the state of your patent protection?

Our intellectual property includes 16 issued and pending patents in the U.S., Canada and Europe, which cover prognostic, risk predictive and monitoring tests for multiple cancers and diseases.

Let’s discuss your lead diagnostic programs. Can you update your progress in Hodgkin’s lymphoma (HL)?

We are in the final stages of validating our Telo-HL test in a study of 250-to-300 retrospective HL patients and hope to have the test on the market by the first quarter of 2018. This is a prognostic test for clinicians with newly diagnosed HL patients to determine a patient’s likelihood of responding to standard chemotherapy or whether a patient is likely to fail standard chemotherapy and relapse. So Telo-HL is designed to stratify HL patients at the point of diagnosis into non-relapsing and relapsing patients. Relapsing patients may then be considered for alternative treatments at the time of diagnosis rather than waiting until they have failed multiple rounds of standard chemotherapy. There is currently no biomarker available that can predict patient response to standard chemotherapy in HL patients.

To see the rest of the interview, please click here.